This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
KAEL Co. Ltd.
Drug Names(s): EP-1043
Description: EP-1043 is an epitope-based (ie, an antigen site recognized by an antibody) recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte responses. The vaccine consists of a string of 18 HIV-derived major histocompatibility complex (MHC) Class II restricted epitopes, each separated by a spacer designed to optimize potency.
Deal Structure: EP-1043 was acquired by Pharmexa from IDM Pharma in late 2005.
In April 2009, VaxOnco (a subdidiary of the Korean company KAEL) acquired Pharmexa-Epimmune (Pharmexa) by the purchase of all outstanding shares from Pharmexa A/S for 440,000. VaxOnco will thus assume all rights and responsibilities relating to the Pharmexa-Epimmune patent portfolio.
Additional information available to subscribers only: